Abstract:Anthrax, caused by the bacterium Bacillus anthracis, can be a highly lethal acute disease in humans and animals. Prior to the 20th century, it led to thousands of deaths each year. Anthrax infection became extremely rare in the United States in the 20th century, thanks to extensive animal vaccination and anthrax eradication programs. The 2001 anthrax attacks in the United States drew this formidable disease back into the public spotlight. Anthrax spores have not long been used in biological warfare or as a terrorism weapon, but anthrax has been on the bioterrorism (BT) agent list for a long time. U.S. military personnel are now routinely vaccinated against anthrax prior to active service in places where biological attacks are considered a threat. The current FDA-licensed vaccine, anthrax vaccine adsorbed (AVA), is produced from a nonvirulent strain of the anthrax bacterium. The licensed regimen for AVA is subcutaneous administration of a series of six primary doses (zero, two, and four weeks and six, 12, and 18 months), followed by annual booster doses. In 1998, a pilot study conducted by the U.S. Department of Defense provided preliminary data suggesting AVA could be given intramuscularly and without the two-week dose, reducing adverse events and not adversely impacting immunogenicity. Since 2000, the CDC has been planning and conducting a clinical trial, the Anthrax Vaccine Research Program (AVRP), to evaluate a reduced AVA schedule and a change in the route of administration in humans. The AVA trial is a 43-month prospective, randomized, double-blind, placebo-controlled trial for the comparison of immunogenicity (i.e., immunity) and reactogenicity (i.e., side effect) elicited by AVA given by different routes of administration and dosing regimens. Administration is subcutaneous (SQ) versus intramuscular (IM). Dosing regimens require as many as eight doses versus as few as four doses. In the AVRP, sterile saline is used as the placebo when a dose is not actually administered. The trial is being conducted among 1,005 healthy adult men and women (18–61 years of age) at five U.S. sites. Participants were randomized into one of seven study groups. One group receives AVA as currently licensed (SQ with six doses followed by annual boosters). Another group receives saline IM or SQ at the same time points as the currently licensed regimen. The five other groups receive AVA IM: one group at the same time points as the currently licensed regimen and the remaining groups in modified dosing regimens. Placebo is given when a dose of AVA is omitted from the licensed dosing regimen. There are 25 required visits over 42 months, during which all participants receive an injection of vaccine or placebo (eight injections total), have a blood sample drawn (16 total), and have an in-clinic examination for adverse events (22 total). Total anti-protective antigen IgG antibody (anti-PA IgG levels) is measured using a standardized and validated enzyme-linked immunosorbent assay (ELISA). The primary study endpoints are four-fold rise in antibody titer, geometric mean antibody concentration, and titer. All adverse events, Multiple Imputation in the Anthrax Vaccine Research Program

[Delayed hypersensitivity in man after booster anthrax vaccination]

Multiple Imputation in the Anthrax Vaccine Research Program

Anthrax Vaccination, Gulf War Illness, and Human Leukocyte Antigen (HLA)

Anthrax Vaccines in the 21st Century

COVID-19 Booster Vaccination Adverse Effects and Willingness to Receive a Yearly Booster Dose among Members of Health Sciences Faculties: A Descriptive Cross-Sectional Study

Pathological skin manifestations following smallpox vaccination (ACAM2000) in US military personnel, 2009-2023: a systematic review

Specific, Sensitive, and Quantitative Enzyme-Linked Immunosorbent Assay for Human Immunoglobulin G Antibodies to Anthrax Toxin Protective Antigen

368. A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Immunogenicity and Safety of AV7909 for Post-exposure Prophylaxis of Anthrax in Healthy Adults

Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose

Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study

The One Year Effects of Three Doses of Hepatitis B Vaccine As a Booster in Anti-Hbs-negative Children 11–15 Years after Primary Immunization; China, 2009–2011

Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster

Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination

Immune response to one booster dose of inactivated hepatitis A vaccine in college students

BG08 Boosting the cutaneous chronicle of the COVID-19 vaccine: it’s not over yet

Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901

Tolerance of the human brucellosis vaccine and the intradermal reaction test for brucellosis

Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age

Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy

[Safety and Immunogenicity of a New Inactivated Hepatitis A Vaccine].